Cargando…
Evaluation of Information Theoretic Network Meta-analysis to Rank First-Line Anticancer Regimens for Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
IMPORTANCE: Hormone receptor–positive, ERBB2 (formerly HER2/neu)-negative metastatic breast cancer (HR-positive, ERBB2-negative MBC) is treated with targeted therapy, endocrine therapy, chemotherapy, or combinations of these modalities; however, evaluating the increasing number of treatment options...
Autores principales: | Li, Xuanyi, Beeghly-Fadiel, Alicia, Bhavnani, Suresh K., Tavana, Hossein, Rubinstein, Samuel M., Gyawali, Bishal, Riaz, Irbaz Bin, Fernandes, H. Deepika, Warner, Jeremy L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008500/ https://www.ncbi.nlm.nih.gov/pubmed/35416993 http://dx.doi.org/10.1001/jamanetworkopen.2022.4361 |
Ejemplares similares
-
Overcoming the Straw Man Effect in Oncology: Visualization and Ranking of Chemotherapy Regimens Using an Information Theoretic Approach
por: Warner, Jeremy L., et al.
Publicado: (2017) -
Platelets, Thrombocytosis, and Ovarian Cancer Prognosis: Surveying the Landscape of the Literature
por: Hufnagel, Demetra H., et al.
Publicado: (2020) -
Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas
por: Zoi, Ilianna, et al.
Publicado: (2019) -
Objective response rate of placebo in randomized controlled trials of anticancer medicines
por: Sachdev, Arushi, et al.
Publicado: (2022) -
Modeling the Impact of Delaying Bariatric Surgery due to COVID-19: a Decision Analysis
por: Shipe, Maren E., et al.
Publicado: (2020)